SCHEMBL6437200

SCHEMBL6437200

COc1cccc(CN(CC(=O)OC(C)(C)C)S(=O)(=O)c2ccc3c(Cl)cnc(NC(=N)N)c3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 3/20 0.46
TAS2R14 Q9NYV8 6/20 0.41
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MMP13 P45452 2/20 0.40
ADAM10 O14672 1/20 0.40
ADAM17 P78536 1/20 0.40
MEP1A Q16819 1/20 0.40
MEP1B Q16820 1/20 0.40
CXCR3 P49682 1/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.39
DAGLA Q9Y4D2 1/20 0.38
PTGER2 P43116 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MMP1 P03956 1/20 0.37
MMP8 P22894 1/20 0.37
BMP1 P13497 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6437195 0.99 PLAU (0.46) PLAUTAS2R14MMP2MMP9MMP13
SCHEMBL6437213 0.92 PLAU (0.46) PLAUTAS2R14MMP2MMP9MMP13
SCHEMBL6434142 0.92 PLAU (0.50) PLAUTAS2R14MMP2MMP9MMP13
Hydrochloric Acid SCHEMBL6438528 0.91 PLAU (0.46) PLAUTAS2R14MMP2MMP9MMP13
Hydrochloric Acid SCHEMBL6434136 0.91 PLAU (0.49) PLAUTAS2R14MMP2MMP9MMP13
SCHEMBL6432627 0.91 PLAU (0.56) PLAUMMP2MMP9MMP13LMNA
SCHEMBL6433152 0.90 PLAU (0.57) PLAUTAS2R14MMP2MMP9MMP13
SCHEMBL6434978 0.88 PLAU (0.47) PLAUMMP2MMP9MMP13ADAM17
SCHEMBL6433815 0.88 PLAU (0.47) PLAUTAS2R14MMP2MMP9MMP13
SCHEMBL6434470 0.88 PLAU (0.44) PLAUALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TAS2R14 2998/4885MMP2 19/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885TAS2R14 2998/4885MMP2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.